New tool developed to assess fall risks in older adults

Rarely does the FDA pub­licly re­lease its rea­son­ing for re­ject­ing a po­ten­tial new drug. But for DC-based Van­da Phar­ma­ceu­ti­cals’ gas­tro­pare­sis drug, the FDA on Wednes­day

Share this article Biora Therapeurics is preparing an ulcerative colitis therapy. Credit: Emily frost via Shutterstock. The US Food and Drug Administration (FDA) cleared Biora